NHC (NYSE: NHC) CFO granted 14,000 stock options under 2020 plan

Rhea-AI Filing Summary

National Healthcare Corp SVP and CFO Brian F. Kidd received a grant of 14,000 options to purchase common stock on February 23, 2026. The options were granted at an exercise price of $0.00 under the 2020 Omnibus Equity Incentive Plan and are exempt from Section 16(b) under Rule 16b-3(d).

The options vest ratably over three years, with one-third vesting on February 23, 2027, one-third on February 23, 2028, and the final one-third on February 23, 2029. As of this grant, Kidd also directly held other option positions and 23,717 shares of common stock.

Insider Trade Summary

5 transactions reported

Mixed 5 txns

Insider KIDD BRIAN F

Role SVP, CFO

Type	Security	Shares	Price	Value
Grant/Award	Option to Purchase Common Stock	14,000	$0.00	--
holding	Option to Purchase Common Stock	--	--	--
holding	Option to Purchase Common Stock	--	--	--
holding	Option to Purchase Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Option to Purchase Common Stock — 14,000 shares (Direct); Common Stock — 23,717 shares (Direct)

Footnotes (1)

1. These stock options were granted pursuant to the 2020 Omnibus Equity Incentive Plan on February 23, 2026. The grant and exercise of these stock options are exempt from Section 16(b) pursuant to Rule 16b-3(d). These stock options will become vested and exercisable ratably over three (3) years so that one-third (1/3) will vest on February 23, 2027; one-third (1/3) will vest on February 23, 2028; and the final one-third (1/3) will vest on February 23, 2029.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KIDD BRIAN F

(Last) (First) (Middle)

100 VINE STREET

(Street)

MURFREESBORO TN 37130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NATIONAL HEALTHCARE CORP [ NHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, CFO

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								23,717	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	$53.94							03/08/2024	03/08/2028	Common Stock	8,000		8,000	D
Option to Purchase Common Stock	$94.1							03/05/2025	03/05/2029	Common Stock	8,000		8,000	D
Option to Purchase Common Stock	$90.62							02/24/2026	02/24/2030	Common Stock	13,500		13,500	D
Option to Purchase Common Stock	$157.13	02/23/2026		A		14,000(1)		02/24/2027(2)	02/24/2031	Common Stock	14,000	$0	14,000	D

Explanation of Responses:

1. These stock options were granted pursuant to the 2020 Omnibus Equity Incentive Plan on February 23, 2026. The grant and exercise of these stock options are exempt from Section 16(b) pursuant to Rule 16b-3(d).

2. These stock options will become vested and exercisable ratably over three (3) years so that one-third (1/3) will vest on February 23, 2027; one-third (1/3) will vest on February 23, 2028; and the final one-third (1/3) will vest on February 23, 2029.

	/s/ Brian Kidd	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did NHC SVP and CFO Brian Kidd report on this Form 4 for NHC?

Brian F. Kidd, SVP and CFO of National Healthcare Corp (NHC), reported receiving a grant of 14,000 options to purchase common stock. The options were awarded at an exercise price of $0.00 under the company’s 2020 Omnibus Equity Incentive Plan.

How many NHC stock options were granted to CFO Brian Kidd?

Kidd was granted 14,000 options to purchase National Healthcare common stock. These options were issued on February 23, 2026, as part of an equity incentive award under the 2020 Omnibus Equity Incentive Plan and are treated as an acquisition transaction on the Form 4.

What is the vesting schedule for Brian Kidd’s 14,000 NHC stock options?

The 14,000 stock options vest ratably over three years. One-third vests on February 23, 2027, another third on February 23, 2028, and the final third on February 23, 2029, creating a multi-year retention and incentive structure for the executive.

Under which plan were Brian Kidd’s NHC stock options granted?

The options were granted under National Healthcare Corp’s 2020 Omnibus Equity Incentive Plan. This plan authorizes equity-based awards to executives and other participants, and the Form 4 specifies that the grant is exempt from Section 16(b) under Rule 16b-3(d).

How many NHC common shares does Brian Kidd hold after this Form 4 event?

The Form 4 shows Brian Kidd directly holding 23,717 shares of National Healthcare common stock. This share figure reflects his direct ownership position as of the reported date and is separate from his various option holdings disclosed in the same filing.

Are Brian Kidd’s new NHC options subject to Section 16(b) short-swing rules?

The filing states these stock options are exempt from Section 16(b) under Rule 16b-3(d). That rule generally allows board-approved grants and awards to insiders without triggering short-swing profit recovery, provided the specific regulatory conditions for the exemption are satisfied.